Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2016.035 | Whole–body vibration training for residents in a care and attention home in Hong Kong and its influence on balance and mobility: a pilot study |
Ms. LUK Ho Yan 陸可欣 |
| 2008.401 | The Effect of Vital Signs Obtained at Prehospital and Emergency Department's Triage Station on Impatient Admission | Miss LUK Joies Ka Yan |
| 2009.414 | The effect of visual stimulation on the adult patient | Mr. LUK Kar Yiu |
| 2013.399 | Focused Ultrasound Screening for Precutaneous Dilatational Tracheostomy | Dr. LUK Leona Wing Kun |
| 2011.493 | Hand eczema among inhabilitants of a public housing estate in Hong Kong: a self-administered questionnaire survey | Dr Luk Nai Ming |
| 2008.190 | Efficacy and Safety of Topical Photodynamic Therapy for Actinic Keratosis among Chinese Patients | Dr. LUK Nai Ming |
| 2009.437 | Efficacy of intralesional 5-fluorouracil in treatment of keloid scar : a randomized-control trial | Dr. LUK Nai Ming |
| 2007.318 | Efficacy and Safety of Diphencyprone (DCP) in the Treatment of Extensive Alopecia Areata in Chinese Patient | Dr. LUK Nai Ming |
| 2013.347 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei | Dr. LUK Sally Wai Yin |
| 2014.406 | Effects of thromboelastography-guided transfusion algorithm versus standard clinical practice on post-operative bleeding and blood product use after cardiac surgery: a randomized, controlled trial | Dr. LUK Ting Hin |
| 2005.471 | Infliximab Induction Therapy for Moderate-to Severe Plaque-Type Psoriasis: An Open-Label, Single Arm Observational Study Evaluating the Efficacy of Use In Hong Kong Chinese Patients | Prof. LUK Tommy Nai Ming |
| 2023.551 | Impact of Injury Prevention Program on Ankle stability for ballet dancers | Ms. LUK Tsz Yan |
| 2005.264 | Psychological Distress, Quality of Life and Marital Relationship among Renal Patients Receiving Continuous Ambulatory Peritoneal Dialysis | Ms. LUK Yvonne Pik Shan |
| 2012.439 | Cross Sectional Survey on Advance Care Planning Acceptance & End of Life Care Preferences among community dwelling elderly with complex medical problems and their carers | Dr LUM Chor Ming |
| 2020.411 | A one–year prospective study for intrapleural pressure for thoracentesis | Dr. LUN Chung Tat |
| 2015.247 | Metformin-associated lactic acidosis requiring intensive care in regional hospitals in Hong Kong and predictive factors for mortality | Dr. LUN Chung Tat |
| 2021.245 | A COPD control questionnaire in a regional hospital during covid-19 pandemic | Dr. Lun Chung Tat |
| 2021.246 | an asthma control questionnaire in a regional hospital during covid-19 pandemic | Dr. LUN Chung Tat |
| 2018.407 | Prospective observational cohort study to assess the ability of mechanically-ventilated patients to press buttons on a smartphone application | Miss LUNG Catherine Chi Yan |
| 2008.417 | An Asia Pacific Non-Randomized, Open-Label Phase II Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab (Erbitux) or FOLFOX Plus Cetuximab as First-Line Therapy in Subjects with KRAS Wild-Type Metastatic Colorectal Cancer (APEC-Study) | Prof. MA Brigette |
| 2023.693 | Perspectives on illness perception and self-management behaviours from patients with non-alcoholic fatty liver disease and healthcare professionals: An exploratory qualitative study | Ms. MA Angel Cho Kan |
| 2023.300 | A nurse-led lifestyle modification intervention for enhancing self-efficacy, illness perception, self-care management and steatosis grade among patients with non-alcoholic fatty liver disease: A randomised controlled trial | Ms. MA Angel Cho Kan |
| 2024.264 | A nurse-led lifestyle modification intervention for enhancing self-efficacy, illness perception, self-care management and steatosis grade among patients with metabolic dysfunction-associated steatotic liver disease: A pilot randomised controlled trial | Ms. MA Angel Cho Kan |
| 2008.141 | A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer | Prof. MA Brigette |
| 2009.486 | A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer | Associate Professor Ma Brigette |
| 2008.091 | Multi-Centre International Study of Capecitabine + Bevacizumab as Adjuvant Treatment of Colorectal Cancer (QUASAR 2) | Associate Professor Ma Brigette |
| 2009.222 | A phase I dose escalation, multi-center, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies | Prof. Ma Brigette |
| 2009.223 | A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma | Professor Ma Brigette |
| 2012.192 | A pilot case-control study of second or third line treatment with cetuximab-containing chemotherapy in patients with metastatic colorectal cancer who were previously treated with cetuximab-based chemotherapy | Prof. MA Brigette |
| 2010.604 | Multicenter Phase II Study of MK-2206 in Previously Treated Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma | Prof. MA Brigette |
| 2012.118 | Intensification of pre-operative therapy with multi-agent chemotherapy and concurrent chemoradiotherapy prior to total mesorectal excision surgery in patients with high risk rectal cancer | Prof. MA Brigette |
| 2018.270 | A randomized study of neoadjuvant chemoradiotherapy with or without intensification with the FOLFOXIRI chemo-regimen for high-risk locally advanced rectal cancer |
Prof. MA Brigette 馬碧如 |
| 2019.390 | Comprehensive Precision Oncology Program at The Chinese University of Hong Kong | Prof. MA Brigette |
| 2009.402 | Elucidating predictive biomarkers of response to cetuximab in local populations with advanced colorectal cancer | Prof. MA Brigette |
| 2012.560 | Asian Metastatic Colorectal Cancer Registry | Prof. MA Brigette |
| 2009.230 | Identifying an early indicator of drug efficacy in patients with advanced colorectal cancer - a prospective evaluation of circulating tumor cells, positron-emission tomography scan and RECIST criteria | Prof. MA Brigette |
| 2010.202 | Prospective evaluation of plasma EBV DNA half-life and PET-CT scanning as a new tool in assessing early response to chemotherapy in patients with advanced nasopharyngeal carcinoma | Prof. MA Brigette |
| 2022.262 | A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced cancers | Prof. MA Brigette |
| 2022.243 | daNIS-3: An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer (mCRC) |
Prof. MA Brigette 馬碧如教授 |
| 2015.386 | Multicenter Phase II Study of Nivolumab in Previously Treated Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma | Prof. MA Brigette |
| 2017.470 | Attitudes to supersized seamless trials in oncology (SUMO) - an international survey |
Prof. MA Brigette 馬碧如教授 |
| 2017.110 | Developing patient derived xenograft and cell line models of cancer | Prof. MA Brigette |
| 2014.440 | A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies. | Prof. MA Brigette |
| 2016.001 | Treatment of Recurrent and Advanced Metastatic Colorectal Cancer (TRACC) | Prof. MA Brigette |
| 2015.152 | Phase I/II study of aflibercept and the modified XELIRI regimen in the second-line treatment of metastatic colorectal cancer | Prof. MA Brigette |
| 2016.439 | The immunological mechanism of plasma EBV DNA clearance during radiotherapy in patients with nasopharyngeal carcinoma – a pilot study |
Prof. MA Brigette 馬碧如 |
| 2012.191 | A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care (BSC) versus placebo plus BSC in Asian subjects with metastatic colorectal cancer (CRC) who have progressed after standard therapy (CONCUR) | Prof. Ma Brigette Buig - Yue |
| 2013.392 | A phase Ib trial of LEE011 in combination with everolimus (RAD001) and exemestane in the treatment of postmenopausal women with hormone receptor positive HER2 negative locally advanced or metastatic breast cancer | Prof. MA Brigette Buig Yue |
| 2012.315 | A phase Ib dose escalation/randomized phase II, multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma | Prof. MA Brigette Buig Yue |
| 2012.044 | A Phase 1 Dose Escalation and Pharmacokinetic Study of Alisertib (MLN8237), an Aurora A Kinase Inhibitor, in Adult East Asian Patients With Advanced Solid Tumors or Lymphomas | Dr. Ma Brigette Buig Yue |
Page 159 of 254.